Anna Eshoo: “I hope the Agency takes more definitive action soon.”

I see, as I expressed to you when we spoke, a disconnect between CMS, the FDA, and the VA on new treatments for mild Alzheimer's.

It is stunning to me that someone pays for something, they don't get it, but the person or the entity they paid it to still gets to keep it.

I have to say that I am really deeply disappointed. Deeply disappointed.

I find it hypocritical when I hear time and time and time again that plans are often blocked by PBMs from offering the lowest-priced generic.